RecruitingNCT06571084

New Screening and Diagnostic Cut-off Points of PA Patients

Establishment and Clinical Application Evaluation of Screening and Diagnostic Cut-off Points With Aldosterone and Renin for Primary Aldosteronism Patients


Sponsor

China National Center for Cardiovascular Diseases

Enrollment

770 participants

Start Date

Jan 4, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to establish the screening and diagnostic cut-off points for primary aldosteronism patients by a novel small molecule "sandwich method" aldosterone and renin chemiluminescent immunoassay.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria8

  • -75y;
  • persistent hypertension (BP >150/100 mm Hg), or drug-resistant hypertension;
  • newly diagnosed hypertension;
  • hypertension and spontaneous or diuretic-induced hypokalemia;
  • hypertension with adrenal incidentaloma;
  • hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (<40 years);
  • status as a hypertensive first-degree relative of patients with PA;
  • patients with hypertension and obstructive sleep apnea.

Exclusion Criteria8

  • age <18; BMI ≤ 18.0kg/m2 or ≥ 35.0 kg/m2;
  • a diagnosis of secondary hypertension other than PA;
  • chronic cardiac dysfunction (NYHA III-IV);
  • medium and several kidney dysfunction (Ccr<30ml/min);
  • liver cirrhosis;
  • terminal malignant tumor;
  • recent use of steroids or oral contraceptives;
  • pregnancy or lactation.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Kai-juan Wang

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06571084


Related Trials